AQST Aquestive Therapeutics, Inc.

Nasdaq aquestive.com


$ 7.17 $ 0.16 (2.36 %)    

Wednesday, 15-Oct-2025 12:44:19 EDT
QQQ $ 602.49 $ -1.33 (-0.22 %)
DIA $ 463.47 $ -1.07 (-0.23 %)
SPY $ 665.04 $ -1.73 (-0.26 %)
TLT $ 90.70 $ -0.26 (-0.29 %)
GLD $ 386.06 $ 0.12 (0.03 %)
$ 6.88
$ 7.00
$ 7.16 x 556
$ 7.17 x 458
$ 6.90 - $ 7.17
$ 2.12 - $ 6.97
2,818,330
na
686.1M
$ 1.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-05-2025 01-01-1970 10-K
4 11-04-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-07-2024 03-31-2024 10-Q
7 03-05-2024 12-31-2023 10-K
8 11-06-2023 09-30-2023 10-Q
9 08-07-2023 06-30-2023 10-Q
10 05-02-2023 03-31-2023 10-Q
11 03-31-2023 12-31-2022 10-K
12 11-01-2022 09-30-2022 10-Q
13 08-02-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-08-2022 12-31-2021 10-K
16 11-02-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 05-04-2021 03-31-2021 10-Q
19 03-09-2021 12-31-2020 10-K
20 11-04-2020 09-30-2020 10-Q
21 08-04-2020 06-30-2020 10-Q
22 05-05-2020 03-31-2020 10-Q
23 03-11-2020 12-31-2019 10-K
24 11-05-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 03-14-2019 12-31-2018 10-K
28 11-06-2018 09-30-2018 10-Q
29 09-04-2018 06-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jmp-securities-maintains-market-outperform-on-aquestive-therapeutics-raises-price-target-to-12

JMP Securities analyst Jason Butler maintains Aquestive Therapeutics (NASDAQ:AQST) with a Market Outperform and raises the p...

 aquestive-secures-new-patents-for-needle-free-epinephrine-film-to-treat-severe-allergies

Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing m...

 crinetics-pharmaceuticals-blackberry-perpetua-resources-and-other-big-stocks-moving-higher-on-friday

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceutical...

 ars-pharma-urges-fda-to-delay-approval-of-aquestives-allergic-reaction-treatment

ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardio...

 oppenheimer-maintains-outperform-on-aquestive-therapeutics-raises-price-target-to-8

Oppenheimer analyst Francois Brisebois maintains Aquestive Therapeutics (NASDAQ:AQST) with a Outperform and raises the price...

 fda-confirms-direct-review-path-for-aquestives-allergy-treatment

Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decisio...

 fda-skips-advisory-committee-meeting-for-aquestive-therapeutics-anaphylm-pdufa-date-set-for-january-31-2026

NDA remains on track for FDA PDUFA goal date of January 31, 2026Commercial planning continues enabling rapid launch following a...

 aquestive-prices-85-million-stock-offering-of-2125m-shares-at-4share-to-fund-anaphylm-allergy-drug-launch

Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing m...

 aquestive-secures-75m-funding-tied-to-fda-approval-of-oral-allergy-rescue-drug-anaphylm

Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing m...

 aquestive-therapeutics-affirms-fy2025-sales-guidance-of-44000m-50000m-vs-45059m-est

Aquestive Therapeutics (NASDAQ:AQST) affirms FY2025 sales outlook from $44.000 million-$50.000 million to $44.000 million-$50.0...

 aquestive-therapeutics-q2-eps-014-beats-017-estimate-sales-10003m-miss-11320m-estimate

Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate o...

 aquestive-seeks-approval-for-needle-free-allergy-film-in-canada-and-europe-eyes-global-expansion

Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing m...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION